NO982556D0 - Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC - Google Patents

Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC

Info

Publication number
NO982556D0
NO982556D0 NO982556A NO982556A NO982556D0 NO 982556 D0 NO982556 D0 NO 982556D0 NO 982556 A NO982556 A NO 982556A NO 982556 A NO982556 A NO 982556A NO 982556 D0 NO982556 D0 NO 982556D0
Authority
NO
Norway
Prior art keywords
azt
hiv
alone
treatment
combination
Prior art date
Application number
NO982556A
Other languages
English (en)
Other versions
NO982556L (no
NO317837B1 (no
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO982556L publication Critical patent/NO982556L/no
Publication of NO982556D0 publication Critical patent/NO982556D0/no
Publication of NO317837B1 publication Critical patent/NO317837B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19982556A 1995-12-05 1998-06-04 Anvendelse av forbindelse for fremstilling av et medikament for a inhibere et aspartylproteaseavhengig virus NO317837B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (3)

Publication Number Publication Date
NO982556L NO982556L (no) 1998-06-04
NO982556D0 true NO982556D0 (no) 1998-06-04
NO317837B1 NO317837B1 (no) 2004-12-20

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982556A NO317837B1 (no) 1995-12-05 1998-06-04 Anvendelse av forbindelse for fremstilling av et medikament for a inhibere et aspartylproteaseavhengig virus

Country Status (23)

Country Link
US (1) US5646180A (no)
EP (1) EP0866696B1 (no)
JP (1) JP2000501713A (no)
KR (1) KR19990071750A (no)
CN (1) CN1203530A (no)
AP (1) AP864A (no)
AT (1) ATE279922T1 (no)
AU (1) AU722850B2 (no)
BR (1) BR9611861A (no)
CA (1) CA2238471A1 (no)
CZ (1) CZ291994B6 (no)
DE (1) DE69633680T2 (no)
ES (1) ES2231828T3 (no)
HU (1) HUP9903673A3 (no)
NO (1) NO317837B1 (no)
NZ (1) NZ324603A (no)
OA (1) OA10691A (no)
PL (1) PL187747B1 (no)
PT (1) PT866696E (no)
RU (1) RU2203658C2 (no)
UA (1) UA61902C2 (no)
WO (1) WO1997020554A1 (no)
ZA (1) ZA9610139B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
CZ429398A3 (cs) * 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP1498084B1 (en) * 2000-10-16 2014-06-18 Innovational Holdings, LLC Expandable medical device for delivery of beneficial agent
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
CA2594910A1 (en) * 2005-01-20 2006-07-27 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
US20090081318A1 (en) * 2005-12-23 2009-03-26 Gelbard Harris A Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3
AU2007239494A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CN112426278A (zh) 2014-02-28 2021-03-02 阿坦斯医疗保健产品公司 具有多层折叠吸收芯的吸收性用品
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
US11744748B2 (en) 2018-05-28 2023-09-05 Attends Healthcare Products, Inc. Dryness layer laminate for absorbent articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
ATE279922T1 (de) 2004-11-15
PT866696E (pt) 2005-03-31
AU1148697A (en) 1997-06-27
OA10691A (en) 2001-05-04
HUP9903673A3 (en) 2000-08-28
NO982556L (no) 1998-06-04
EP0866696B1 (en) 2004-10-20
ES2231828T3 (es) 2005-05-16
KR19990071750A (ko) 1999-09-27
DE69633680D1 (de) 2004-11-25
WO1997020554A1 (en) 1997-06-12
US5646180A (en) 1997-07-08
PL327061A1 (en) 1998-11-23
AP9801340A0 (en) 1998-09-30
RU2203658C2 (ru) 2003-05-10
NO317837B1 (no) 2004-12-20
CZ170898A3 (cs) 1998-09-16
CN1203530A (zh) 1998-12-30
BR9611861A (pt) 1999-05-18
ZA9610139B (en) 1997-06-17
CZ291994B6 (cs) 2003-07-16
JP2000501713A (ja) 2000-02-15
HUP9903673A2 (hu) 2000-03-28
UA61902C2 (en) 2003-12-15
DE69633680T2 (de) 2006-02-23
EP0866696A1 (en) 1998-09-30
CA2238471A1 (en) 1997-06-12
AP864A (en) 2000-08-11
NZ324603A (en) 2000-08-25
PL187747B1 (pl) 2004-09-30
AU722850B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
NO982556L (no) Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC
MX9200587A (es) ADICCION DE SMO2 COLOIDAL EN LA PRODUCCION DE TiO2 SUBPIGMENTARIO.
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
BR9101795A (pt) Catalisadores e processo uteis na producao de 1,3-diois e/ou 3-hidroxialdeidos
NL300195I2 (nl) Synergistische combinaties van zidovudine, 1592U89en 3TC of FTC.
DE69306796D1 (de) Herstellung von feststoffen im nano-bereich
FI970214A0 (fi) Droloksifeenin käyttö sydänverisuonitautien hoitamiseksi
BR9708797A (pt) Processo de preparação de partículas as respectivas partículas e utilização das mesmas
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DK0721522T3 (da) Iriserende stoffer.
TR199501501A2 (tr) Sekerlemelerin hazirlanmasi.
NO984760D0 (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
FI973184A0 (fi) Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibiittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdollisesti yhdessä AZT:n, DDI:n tai DDC:n kanssa
NO934311D0 (no) alfa,omega -diarylalkanderivater, deres fremstilling ag anvendelse ved behandling av dirkulasjonssykdommer og psykoser
FR2702149B1 (fr) Application de la lamotrigine dans le traitement du neuro-sida.
DE68913928D1 (de) Viskoelastischer Dämpfungskörper und das dazugehörige Herstellungsverfahren.
DE3886155D1 (de) Anthracyclin-Derivate mit Inhibitorwirkung gegen die reverse Transkriptase des menschlichen Immundefizienzvirus.
DK0866696T3 (da) Behandling af HIV ZNS-effekter med VX-478 alene eller i kombination med AZT eller 3TC
NO944296D0 (no) Diaminer ved behandling av arrhytmi
IT8520873A0 (it) Apparecchio per depurare l'aria in particolare cappa per asportare gli odori da applicare su fornelli da cucina o simili.
NO981460D0 (no) Preparat for behandling og/eller profylakse av hudlidelser, samt anvendelse derav
NO903856D0 (no) Emulgeringsmiddel, invertemulsjoner fremstilt ved hjelp av dette, og anvendelse av invertemulsjonene i borehull.
ES1025665Y (es) Inmovilizador de las extremidades en pacientes que deben permanecer inmoviles.
TH17482EX (th) มือจับก๊อกน้ำ
MX9100767A (es) Mejoras en la fabricacion de hornazas.